Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907-2091, USA.
Vaccine. 2010 Apr 30;28(20):3588-94. doi: 10.1016/j.vaccine.2010.02.085. Epub 2010 Mar 5.
The relationship between depot formation and immunopotentiation was studied by comparing the retention of antigen at the inoculation site with antibody production in rats. A model (111)In-labeled alpha casein (IDCAS) antigen was formulated into four vaccines: IDCAS adsorbed onto either aluminum hydroxide adjuvant (AH) or aluminum phosphate adjuvant (AP); non-adsorbed IDCAS with phosphate-treated AP (PTAP); and IDCAS solution. Gamma scintigraphy showed the order of retention following subcutaneous administration to be: AH adsorbed>AP adsorbed>non-adsorbed with PTAP=solution. The antibody titers followed the order: non-adsorbed with PTAP=AP adsorbed>AH adsorbed>>solution. The presence of an aluminum-containing adjuvant was essential for immunopotentiation, but retention of the antigen at the inoculation site was not required.
我们通过比较抗原在接种部位的保留情况与大鼠的抗体产生情况，研究了贮存库形成与免疫增强之间的关系。将模型（111）In 标记的α-酪蛋白（IDCAS）抗原配制成四种疫苗：吸附于氢氧化铝佐剂（AH）或磷酸铝佐剂（AP）的 IDCAS；用磷酸盐处理的 AP 吸附的非吸附 IDCAS（PTAP）；以及 IDCAS 溶液。γ闪烁显像显示，皮下给药后，其在体内的保留顺序为：吸附 AH>吸附 AP>非吸附并用 PTAP=溶液。抗体效价的顺序为：非吸附并用 PTAP=吸附 AP>吸附 AH>>溶液。铝佐剂的存在对免疫增强是必需的，但不需要抗原在接种部位的保留。
